Premal Thaker | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Premal Thaker | Clinical Trials | Best Researcher Award

Dr. Premal Thaker at Washington University School of Medicine, United States.

Dr. Premal Thaker is a renowned gynecologic oncologist and professor at Washington University, St. Louis. With a medical degree from Allegheny University and advanced training at MD Anderson Cancer Center, she has led impactful clinical research in ovarian and endometrial cancers 🧪. As Director of Gynecologic Oncology Clinical Research and Division Chief (2025–present), her leadership is pivotal in advancing cancer therapies. A respected speaker, grant recipient, and editorial board member 📚, Dr. Thaker has earned numerous accolades including “Best Doctors in America” and “Castle Connolly Top Doctor” 🏅. Her dedication to women’s health continues to inspire globally.

Publication Profile 

Scopus

Education

Dr. Premal Thaker’s illustrious academic journey began with a BA in Biology from Villanova University 🎓, followed by an MD from Allegheny University and an MS in Cancer Biology from the University of Texas 🧬. She completed specialized training in gynecologic oncology at MD Anderson Cancer Center and recently attended a leadership course at Harvard 🏛️. Dr. Thaker has held esteemed positions at Washington University, advancing from Assistant Professor to Division Chief of Gynecologic Oncology 👩‍⚕️. A distinguished researcher and educator, she is also the David and Lynn Mutch Distinguished Professor and Director of Clinical Research.

Awards

Dr. Premal Thaker has received numerous accolades throughout her distinguished career in gynecologic oncology 🎖️. Beginning with academic honors such as the Dean’s List and Alpha Epsilon Delta Honor Society in the early 1990s 📚, she went on to earn prestigious awards for scientific presentations and publications, including the J.G. Moore Award 🧪 and GCF/Eli Lilly Fellow Award 🧬. Recognized as one of the Best Doctors in St. Louis (2013–2025) and America (2020–2024) 👩‍⚕️, she was also named a Castle Connolly Top Doctor and Fellow of AGOS. In 2025, she joined Avant-Garde Health’s Research All-Stars.

Research Focus 

Dr. Premal Thaker’s research primarily centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers 🧫. Her work explores immune checkpoint inhibitors, personalized gene therapy, molecular profiling, and health disparities in clinical trial enrollment, particularly in Hispanic and Asian populations 🌍. She also investigates novel immunotherapy combinations, real-world treatment outcomes, and genomic biomarkers for therapy response and survival 🧪. Her multidisciplinary efforts contribute to precision medicine and the advancement of targeted therapies for women’s reproductive cancers, driving impactful, patient-centered innovations in oncology care.

Publication Top Notes

  • Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
  • OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
  • Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
  • Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
  • Diverse case series of granulomatous peritonitis mimicking advanced ovarian cancer
  • Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
  • Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis
  • Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
  • Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma
  • Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study

Vibeke Strand | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Vibeke Strand | Clinical Trials | Best Researcher Award

Dr. Vibeke Strand, Stanford University, United States

Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology 🎓 and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.

Publication Profile

Scopus

Education

Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 🧠📚. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 🏥💉. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 🔬🧪. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.

Awards

Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field 🧠👏. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Who’s Who in Science and Engineering for her scientific impact 🌟📘. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.

Research Focus

Dr. Vibeke Strand’s research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib 💊📊. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies 📝💼. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.

Publication Top Notes

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents